0001104659-20-138396.txt : 20201222 0001104659-20-138396.hdr.sgml : 20201222 20201222092531 ACCESSION NUMBER: 0001104659-20-138396 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 7 FILED AS OF DATE: 20201222 DATE AS OF CHANGE: 20201222 GROUP MEMBERS: CDH GRIFFIN HOLDINGS CO LTD GROUP MEMBERS: CDH UTOPIA LTD GROUP MEMBERS: CDH VI HOLDINGS CO LTD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SINOVAC BIOTECH LTD CENTRAL INDEX KEY: 0001084201 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: B9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-79318 FILM NUMBER: 201406330 BUSINESS ADDRESS: STREET 1: NO. 15 ZHI TONG ROAD, STREET 2: ZHONGGUANCUN TECH PARK, CHANGPING DISTR. CITY: BEIJING STATE: F4 ZIP: 102200 BUSINESS PHONE: 86-10-82890088 MAIL ADDRESS: STREET 1: NO. 15 ZHI TONG ROAD, STREET 2: ZHONGGUANCUN TECH PARK, CHANGPING DISTR. CITY: BEIJING STATE: F4 ZIP: 102200 FORMER COMPANY: FORMER CONFORMED NAME: NET FORCE SYSTEMS INC DATE OF NAME CHANGE: 19991110 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CDH Fund VI, L.P. CENTRAL INDEX KEY: 0001743091 IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: MAPLES CORPORATE SERVICES LIMITED STREET 2: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGETOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 BUSINESS PHONE: (852) 28107003 MAIL ADDRESS: STREET 1: MAPLES CORPORATE SERVICES LIMITED STREET 2: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGETOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 SC 13D 1 tm2038785d1_sc13d.htm SC 13D

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No.)*

 

Sinovac Biotech Ltd.
(Name of Issuer)
 
Common Shares, $0.001 par value per share
(Title of Class of Securities)
 
P8696W104
(CUSIP Number)
 

Quan Li

CDH Utopia Limited

One Temasek Avenue

#18-02, Millenia Tower,

Singapore 039192

(+65) 65728750
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
 
December 22, 2020
(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. P8696W104

 

1.

NAME OF REPORTING PERSON.

CDH Utopia Limited

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨ (b) x

3. SEC USE ONLY
4.

SOURCE OF FUNDS

WC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7. SOLE VOTING POWER 0
8. SHARED VOTING POWER 1,800,000(1)
9. SOLE DISPOSITIVE POWER 0
10. SHARED DISPOSITIVE POWER 6,000,000(2)

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,000,000(2)

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.44%(3))
14.

TYPE OF REPORTING PERSON

CO

 

(1)            Representing 30% of the total shares of common stock held by CDH Utopia Limited. Please refer to Item 6 of this Schedule 13D for details.

 

(2)            Representing 6,000,000 shares of common stock directly held by CDH Utopia Limited.

 

(3)            The percentage of 8.44% is calculated based on 71,125,902 shares outstanding of the Issuer as of March 31, 2020 according to the Issuer’s annual report on Form 20-F for the fiscal year ended December 31, 2019 (the “2019 Annual Report”), before taking into account the issuance of the Exchange Shares (as defined in the 2019 Annual Report). This percentage would be 5.28% if calculated based on 113,534,056 shares outstanding of the Issuer as of March 31, 2020, taking into account the issuance of the Exchange Shares, according to the 2019 Annual Report.

 

 

 

 

CUSIP No. P8696W104

 

1.

NAME OF REPORTING PERSON.

CDH Fund VI, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨ (b) x

3. SEC USE ONLY
4.

SOURCE OF FUNDS

WC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7. SOLE VOTING POWER 0
8. SHARED VOTING POWER 1,800,000(1)
9. SOLE DISPOSITIVE POWER 0
10. SHARED DISPOSITIVE POWER 6,000,000(2)

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,000,000(2)

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.44%(3)
14.

TYPE OF REPORTING PERSON

PN

 

(1)            Representing 30% of the total shares of common stock held by CDH Utopia Limited. Please refer to Item 6 of this Schedule 13D for details.

 

(2)            Representing 6,000,000 shares of common stock directly held by CDH Utopia Limited.

 

(3)            The percentage of 8.44% is calculated based on 71,125,902 shares outstanding of the Issuer as of March 31, 2020 according to the 2019 Annual Report, before taking into account the issuance of the Exchange Shares (as defined in the 2019 Annual Report). This percentage would be 5.28% if calculated based on 113,534,056 shares outstanding of the Issuer as of March 31, 2020, taking into account the issuance of the Exchange Shares, according to the 2019 Annual Report.

 

   

 

 

CUSIP No. P8696W104

 

1.

NAME OF REPORTING PERSON.

CDH VI Holdings Company Limited

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨ (b) x

3. SEC USE ONLY
4.

SOURCE OF FUNDS

N/A

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7. SOLE VOTING POWER 0
8. SHARED VOTING POWER 1,800,000(1)
9. SOLE DISPOSITIVE POWER 0
10. SHARED DISPOSITIVE POWER 6,000,000(2)

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,000,000(2)

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.44% (3)
14.

TYPE OF REPORTING PERSON

CO

 

(1)            Representing 30% of the total shares of common stock held by CDH Utopia Limited. Please refer to Item 6 of this Schedule 13D for details.

 

(2)            Representing 6,000,000 shares of common stock directly held by CDH Utopia Limited.

 

(3)            The percentage of 8.44% is calculated based on 71,125,902 shares outstanding of the Issuer as of March 31, 2020 according to the 2019 Annual Report, before taking into account the issuance of the Exchange Shares (as defined in the 2019 Annual Report). This percentage would be 5.28% if calculated based on 113,534,056 shares outstanding of the Issuer as of March 31, 2020, taking into account the issuance of the Exchange Shares, according to the 2019 Annual Report.

 

   

 

 

CUSIP No. P8696W104

 

1.

NAME OF REPORTING PERSON.

CDH Griffin Holdings Company Limited

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨ (b) x

3. SEC USE ONLY
4.

SOURCE OF FUNDS

N/A

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7. SOLE VOTING POWER 0
8. SHARED VOTING POWER 1,800,000(1)
9. SOLE DISPOSITIVE POWER 0
10. SHARED DISPOSITIVE POWER 6,000,000(2)

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,000,000(2)

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.44% (3)
14.

TYPE OF REPORTING PERSON

CO

 

(1)            Representing 30% of the total shares of common stock held by CDH Utopia Limited. Please refer to Item 6 of this Schedule 13D for details.

 

(2)            Representing 6,000,000 shares of common stock directly held by CDH Utopia Limited.

 

(3)            The percentage of 8.44% is calculated based on 71,125,902 shares outstanding of the Issuer as of March 31, 2020 according to the 2019 Annual Report, before taking into account the issuance of the Exchange Shares (as defined in the 2019 Annual Report). This percentage would be 5.28% if calculated based on 113,534,056 shares outstanding of the Issuer as of March 31, 2020, taking into account the issuance of the Exchange Shares, according to the 2019 Annual Report.

 

 

 

 

CUSIP No. P8696W104

 

SCHEDULE 13D

 

Item 1. Security and Issuer

 

This statement on Schedule 13D (this “Schedule 13D”) relates to the Common Shares, par value $0.001 per share (the “Common Shares”) of Sinovac Biotech Ltd., an Antigua and Barbuda company (the “Issuer”).

 

The address of the principal executive offices of the Issuer is No. 15 Zhi Tong Road, Zhongguancun Science and Technology Park, Changping District, Beijing 102200, People’s Republic of China.

 

Item 2. Identity and Background

 

(a) and (f)

 

This Schedule 13D is being filed jointly on behalf of CDH Utopia Limited (“CDH Utopia”), CDH Fund VI, L.P. (“CDH Fund VI”), CDH VI Holdings Company Limited (“CDH VI Holdings”), and CDH Griffin Holdings Company Limited (“CDH Griffin”) (each a “Reporting Person”). The agreement among the Reporting Persons relating to the joint filing of this Schedule 13D is attached as Exhibit A hereto. Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of the information concerning the other Reporting Persons.

 

As of the date hereof, CDH Utopia is an exempted company incorporated under the laws of the Cayman Islands. CDH Fund VI, a Cayman Islands limited partnership, owns 100% of the total outstanding shares of CDH Utopia. CDH VI Holdings, a Cayman Islands company, is the general partner of CDH Fund VI and by virtue of its limited partnership agreement has the power to direct CDH Fund VI as to the voting and disposition of shares directly and indirectly entitled to by CDH Fund VI. CDH Griffin, a British Virgin Islands company, owns 100% of the total outstanding shares of CDH VI Holdings.

 

(b) The principal office address of CDH Utopia, CDH Fund VI, CDH VI Holdings and CDH Griffin is c/o One Temasek Avenue, #18-02, Millenia Tower, Singapore 039192. The principal business of the Reporting Persons is investment holding.

 

(c) The name, business address, present principal occupation or employment and citizenship of each of the directors executive officers of each of the Reporting Persons is set forth on Schedule A.

 

(d) and (e) During the last five years, none of the Reporting Persons has, and to the knowledge of the Reporting Person, no person named in Schedule A, (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree or final order enjoining the person from future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or a finding of any violation of federal or state securities laws.

 

Item 3. Source and Amount of Funds

 

The funds used by CDH Utopia to acquire beneficial ownership of the Company’s Common Shares were funded by CDH Fund VI using its own investment capital contributed by investors.

 

On November 24, 2020, CDH Utopia entered into a Share Purchase Agreement (the “Purchase Agreement”) with 1Globe Biomedical (Hong Kong) Company Limited (the “Seller”), pursuant to which CDH Utopia purchased 6,000,000 Common Shares (“Sale Shares”) of the Issuer from the Seller for an aggregate purchase price of $90,000,000, or $15.00 per share, on December 18, 2020. The Purchase Agreement is attached as Exhibit B to this Schedule 13D. Any description of the Purchase Agreement is qualified in its entirety by reference thereto.

 

   

 

 

Item 4. Purpose of Transaction

 

The acquisition by CDH Utopia of the Common Stock as described herein was effected because of the belief that the shares of Common Stock represent an attractive investment. CDH Utopia beneficially owns, and the other Reporting Persons, as applicable, may be deemed to beneficially own, the Common Stock as an investment. Depending on prevailing market, economic and other conditions, the Reporting Persons may from time to time acquire additional Common Stock or engage in discussions with the Company concerning future acquisitions of shares of its capital stock. Such acquisitions may be made by means of open-market purchases, privately negotiated transactions, direct acquisitions from the Company or otherwise. The Reporting Persons intend to review their investment in the Company on a continuing basis and, depending upon the price and availability of shares of the Company’s capital stock, subsequent developments affecting the Company, the Company’s business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Company.

 

Pursuant to the Purchase Agreement, CDH Utopia and the Seller shall use their reasonable best efforts to procure a person nominated by CDH Utopia and a person nominated by the Seller be appointed or elected as members of the board of directors of the Company.

 

In connection with the Purchase Agreement, CDH Utopia entered into a letter agreement on November 24, 2020 (as amended on December 18, 2020, the “Letter Agreement”) with the Seller and CDH Investment Advisory Private Limited. Under the Letter Agreement, it was agreed, among other things, that (i) CDH Utopia shall make to the Seller or its designee a lump sum payment of $135,600,000 as compensation and reimbursement for, among other terms and conditions, the total costs and expenses that have been incurred and are estimated to be incurred by the Seller and its affiliates in connection with certain legal proceedings to which the Seller and its affiliates are parties; and (ii) CDH Utopia shall cast shareholder votes representing 70% of the Sale Shares then held by CDH Utopia in accordance with the voting instructions given by the Seller. Further, pursuant to the Letter Agreement, CDH Utopia and the Seller agree that, subject to detailed arrangement to be further discussed, CDH Utopia shall be entitled to the greater of (i) 30% of all proceeds received by CDH Utopia in respect of the disposal or divestment of the Sale Shares or (ii) such portion of the proceeds that would allow the Purchaser to generate a net return which yields twice the investment cost of CDH Utopia, or the entire proceeds if the proceeds are insufficient to generate such net return, and then the remainder of the proceeds upon deduction of the distribution to CDH Utopia shall be distributed to the Seller. The original Letter Agreement and the Amendment to the Letter Agreement are attached as Exhibit C and Exhibit D to this Schedule 13D, respectively. Any description of the Letter Agreement is qualified in its entirety by reference thereto.

 

Except as set forth herein, the Reporting Persons have no present plans or proposals that relate to or that would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act.

 

Item 5. Interest in Securities of Issuer

 

  (a) The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Schedule 13D.
     
  (b) The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages and in Item 6 to this Schedule 13D.

 

  (c) Except as disclosed herein, the Reporting Person has not, and to the knowledge of the Reporting Persons, no Person named in Schedule A hereto has, effected any other transactions in the securities of the Issuer during the past 60 days.

 

(d) The information set forth in Item 4 of this Schedule 13D is incorporated herein by reference. Except as otherwise described in this statement, to the knowledge of the Reporting Persons, no person other than the Reporting Persons, has the power to direct the receipt of dividends on or the proceeds of sales of, the Common Shares owned by the Reporting Person.
   
(e) Not Applicable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

 

The information set forth in Items 2, 3 and 4 of this Schedule 13D and the Exhibits to this Schedule 13D are incorporated herein by reference.

 

Except as described herein, there are no contracts, arrangements, understandings or relationships among the persons named in Item 2 above or between such persons and any other person with respect to any securities of the Company.

 

Item 7. Material to be Filed as Exhibits.

 

Exhibit A – Joint Filing Agreement, dated December 22, 2020, among the Reporting Persons, relating to the filing of a joint statement on Schedule 13D
Exhibit B – Purchase Agreement, dated November 24, 2020.
Exhibit C – Letter Agreement Regarding the Proposed Investment by CDH, dated November 24, 2020.
Exhibit D – Amendment to the Letter Agreement Regarding the Proposed Investment by CDH, dated December 18, 2020.

 

 

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: December 22, 2020

 
  CDH Utopia Limited
   
  By: /s/ William Hsu
    Name: William Hsu
    Title: Director  
     
  CDH Fund VI, L.P.
   
  By: CDH VI Holdings Company Limited, its general partner
   
  By: /s/ Jiao Shuge
    Name: Jiao Shuge
    Title: Director  
     
  CDH VI Holdings Company Limited
   
  By: /s/ Jiao Shuge
    Name: Jiao Shuge
    Title: Director
       
  CDH Griffin Holdings Company Limited
   
  By: /s/ Jiao Shuge
    Name: Jiao Shuge
    Title: Director

 

   

 

 

Schedule A

 

 

Name Citizenship Present Principal Occupation or Employment and Business Address
Shuge Jiao Singapore

Director of CDH VI Holdings Company Limited and CDH Griffin Holdings Company Limited

 

1503 International Commerce Center, 1 Austin Road West, Kowloon, Hong Kong

William Hsu Taiwan

Director of CDH Utopia Limited

 

One Temasek Avenue, #18-02 Millenia Tower, Singapore 039192

 

 

   

 

EX-99.A 2 tm2038785d1_ex99-a.htm EXHIBIT A

EXHIBIT A

 

 

 

JOINT FILING AGREEMENT

 

Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13D is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements. Each of the undersigned acknowledges that it shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

 

Dated: December 22, 2020

 

  CDH Utopia Limited
   
  By: /s/ William Hsu
    Name: William Hsu
Title: Director  
     
 

CDH Fund VI, L.P.

 

By: CDH VI Holdings Company Limited, its general partner

   
  By: /s/ Jiao Shuge
    Name:  Jiao Shuge
Title: Director
     
  CDH VI Holdings Company Limited
   
  By: /s/ Jiao Shuge
    Name: Jiao Shuge
Title: Director
     
  CDH Griffin Holdings Company Limited
   
  By: /s/ Jiao Shuge
    Name: Jiao Shuge
Title: Director  

 

 

 

EX-99.B 3 tm2038785d1_ex99-b.htm EXHIBIT B

EXHIBIT B

 

SHARE PURCHASE AGREEMENT

 

This SHARE PURCHASE AGREEMENT (this “Agreement”) dated as of November 24, 2020 is made by and between CDH Utopia Limited, a company incorporated and existing under the laws of the Cayman Islands (the “Purchaser”), and 1Globe Biomedical (Hong Kong) Company Limited, a company incorporated under the laws of Hong Kong (theSeller”). The Purchaser and the Seller are hereinafter referred to as the “Parties” and each a “Party.”

 

WHEREAS, the Seller desires to sell to the Purchaser, and the Purchaser desires to purchase from the Seller, all of the Seller’s right, title and interest in and pertaining to an aggregate of 6,000,000Common Shares of Sinovac Biotech Ltd., a company incorporated in Antigua, West Indies (the “Company”) (the “Sale Shares”), all upon the terms and conditions set forth in this Agreement.

 

NOW THEREFORE, in consideration of the foregoing and the mutual promises, covenants and agreements of the Parties contained herein, the Parties agree as follows:

 

Article I
DEFINITIONS

 

1.1          Definitions. The following terms shall have the following meanings for purposes of this Agreement:

 

Acquisition Proposal” means any offer, proposal or indication of interest in the acquisition of any or all of the Sale Shares.

 

Business Day” means a day other than any Saturday, any Sunday or any day on which banks located in Antigua, Hong Kong, the People’s Republic of China, the Cayman Islands, Singapore or the United States are authorized or obligated to close.

 

Common Shares” means common shares, par value US$0.001 per share, of the Company.

 

Exchange Act” means U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

Government Authority” means any government or political subdivision thereof, whether on a federal, central, state, provincial, municipal or local level and whether executive, legislative or judicial in nature, including any agency, arbitrator, authority, board, bureau, commission, court, department, official, tribunal or other instrumentality thereof.

 

Law” means any law, treaty, statute, ordinance, code, rule or regulation of any Government Authority or any Order.

 

Material Adverse Effect” means, with respect to a Person, any event, circumstance, development, change or effect that, individually or in the aggregate, has or would reasonably be expected to have a material adverse effect on the financial condition or results of operations or the assets and liabilities of such Person or the capability to perform said Person’s obligations under this Agreement, excluding any such effect resulting from (A) the announcement of the transactions contemplated by this Agreement, (B) changes affecting any of the industries such Person operates generally or the economy generally but not affecting such Person disproportionately or (C) changes affecting general worldwide economic or capital market conditions but not affecting such Person disproportionately.

 

 

 

 

Order” means any writ, judgment, decree, injunction, award or similar order of any Government Authority (in each such case whether preliminary or final).

 

Organizational Documents” means, with respect to an entity, its certificate of incorporation, articles of incorporation, by-laws, articles of association, memorandum of association, certificate of trust, trust agreement, partnership agreement, limited partnership agreement, certificate of formation, limited liability company agreement or operating agreement, as applicable.

 

Per Share Consideration” means US$15.00, as may be adjusted from time to time for any share splits, share dividends, combination, recapitalizations and similar transactions.

 

Person” means an individual, firm, corporation, partnership, association, limited liability company, union, trust or estate or any other entity or organization whether or not having separate legal existence, including any Government Authority.

 

Securities Act” means the U.S. Securities Act of 1933, as amended.

 

US$” means the United States Dollar, the lawful currency of the United States of America.

 

Article II
PURCHASE AND SALE

 

2.1          Purchase and Sale. Subject to and upon the fulfillment of the terms and conditions set forth in this Agreement, the Purchaser shall purchase and acquire from the Seller, and the Seller shall sell and deliver to the Purchaser, the Sale Shares and all of the Seller’s right, interest and title therein (including all dividends and distributions attaching thereto on or after the date hereof), for an aggregate purchase price of US$90,000,000 (the “Purchase Price”), representing the Per Share Consideration per Common Share.

 

2.2          Closing.

 

(a)           The closing of the purchase and sale of all Sale Shares contemplated hereunder (the “Closing”) shall take place on the date that is the fifteenth (15th) Business Day following the date upon which all of the conditions set forth in Article VI are satisfied or waived (other than those that by their nature may only be satisfied at the Closing, but subject to the satisfaction or waiver of such conditions at the Closing), or such other date as may be agreed by the Purchaser and the Seller (the “Closing Date”).

 

(b)           At the Closing, the Seller shall deliver, or cause to be delivered, the following to the Purchaser against payment of the Purchase Price by the Purchaser: (i) originals of one or more certificates representing the Sale Shares, (ii) a duly executed instrument of transfer from the Seller in respect of the Sale Shares in favor of the Purchaser in accordance with the then-effective Organizational Documents of the Company; (iii) copies of the director and shareholder resolution of the Seller duly authorizing and approving this Agreement and the transactions contemplated hereby; (iv) such other documents as may be required by the transfer agent in order to complete the transfer of the Sale Shares from the Seller to the Purchaser; and (v) direct the Company to take all necessary and desirable actions to reflect the same in its or its transfer agent’s books and records.

 

-2

 

 

(c)           At the Closing, the Purchaser shall deliver, or cause to be delivered, to the Seller immediately available funds by wire transfer into an account (which shall be designated by the Seller no later than five (5) Business Days prior to the Closing Date) in the amount of the Purchase Price.

 

(d)           Unless otherwise agreed by the Parties, all actions at the Closing are inter-dependent and will be deemed to take place simultaneously and no delivery or payment will be deemed to have been made until all deliveries and payment under this Agreement due to be made at the Closing have been made.

 

Article III
REPRESENTATIONS AND WARRANTIES OF THE SELLER

 

The Seller hereby represents and warrants to the Purchaser as of the date hereof and as of the Closing Date as follows:

 

3.1          Authority; Binding Effect. The Seller has the requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. All corporate action on the part of the Seller and its officers, directors and shareholders necessary for the authorization, execution and delivery of this Agreement and the performance of all of its obligations hereunder, including the sale of the Sale Shares, have been taken prior to the Closing. This Agreement has been duly and validly executed and delivered by of the Seller, and (assuming the due execution and delivery thereof by the Purchaser) constitutes the legal, valid and binding obligations of the Seller, enforceable against the Seller in accordance with its terms.

 

3.2          No Conflict. The execution and delivery by the Seller of this Agreement and the consummation of the transactions contemplated herein and compliance by the Seller with its obligations hereunder do not and will not, whether with or without the giving of notice or passage of time or both, (i) conflict with or constitute a breach of, or default under, require any consent or other actions by any Person under, give rise to any right of termination, cancellation or acceleration of any right or obligation of any Person or to a loss of any benefit to which the Seller is entitled, or result in the creation or imposition of any tax or Encumbrance upon the Sale Shares or any property or assets of the Seller, pursuant to any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, license, lease or other agreement or instrument to which the Seller is a party or by which the Seller is bound, or to which any of the properties or assets of the Seller is subject, or (ii) result in any violation of the provisions of the Organizational Documents of the Seller or the Company, or any applicable Laws.

 

3.3          Ownership and Transfer. Immediately prior to the Closing, the Seller shall have become the sole record and beneficial owner of the Sale Shares, free and clear of all security interests, claims (pending or threatened), liens, pledges, charges, equities or other encumbrances, limitations or restrictions (including any restriction on the right to vote, sell or otherwise dispose of the Sale Shares) (“Encumbrances”), and will transfer and deliver to the Purchaser at the Closing valid, good and marketable title to the Sale Shares free and clear of any Encumbrances.

 

3.4          Consents. No filing with, or consent, approval, authorization, order, registration, qualification or decree of, or any other action by or in respect of, any court or Governmental Authority, is necessary or required for the execution and delivery of this Agreement, the performance by the Seller of its obligations hereunder or the sale and delivery of the Sale Shares or the consummation of the transactions contemplated hereunder.

 

-3

 

 

3.5          Seller’s Status. The Seller is a sophisticated investor with sufficient investment or financial knowledge and experience as well as knowledge in the Company, which enable the Seller to properly evaluate the risks and merits of its participation in the transaction contemplated hereunder and protect its own interest in connection therewith. The Seller has made a determination based on its own independent review and such professional advice as it deems appropriate that (i) the Seller’s consideration of the sale of the Sale Shares to the Purchaser in the transaction contemplated hereunder is fully consistent with its financial needs, objectives and condition, and (ii) the terms of the transaction contemplated hereunder have been agreed through arm’s-length negotiation and are fair to the Seller.

 

3.6          Exempt Offering. Assuming the accuracy of the Purchaser’s representations and warranties herein, the offer and sale of the Sale Shares under this Agreement are or will be exempt from the registration requirements and prospectus delivery requirements of the Securities Act, and from the registration or qualification requirements of any other applicable securities laws and regulations.

 

3.7          Litigation. There are no pending or, to the knowledge of the Seller, threatened actions, claims, demands, investigations, examinations, indictments, litigations, suits or other criminal, civil or administrative or investigative proceedings before or by any Governmental Authority or by any other Person against the Seller, except that would not be reasonably expected to have a Material Adverse Effect, or any proceedings that seek to restrain or enjoin the consummation by the Seller of the transactions contemplated hereunder.

 

3.8          Purchaser’s Reliance. The Seller acknowledges and agrees that the Purchaser is relying on the representations, warranties and agreements of the Seller herein in proceeding with the transaction contemplated hereunder. Without such representations, warranties and agreements, the Purchaser would not engage in the transaction contemplated hereunder.

 

Article IV
REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

 

The Purchaser hereby represents and warrants to the Seller as of the date hereof and as of the Closing Date as follows:

 

4.1          Authority; Binding Effect. The Purchaser has the requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. All corporate action on the part of the Purchaser and its officers, directors and shareholders necessary for the authorization, execution and delivery of this Agreement and the performance of all of its obligations hereunder, including the purchase of the Sale Shares, have been taken prior to the Closing. This Agreement has been duly and validly executed and delivered by the Purchaser, and (assuming the due execution and delivery thereof by the Seller) constitutes the legal, valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms.

 

4.2          No Conflict. The execution and delivery by the Purchaser of this Agreement and the consummation of the transactions contemplated herein and compliance by the Purchaser with its obligations hereunder do not and will not, whether with or without the giving of notice or passage of time or both, (i) conflict with or constitute a breach of, or default under, require any consent or other action by any Person under, give rise to any right of termination, cancellation or acceleration of any right or obligations of any Person or to a loss of any benefit to which the Purchaser is entitled, or result in the creation or imposition of any tax or Encumbrance upon any property or assets of the Purchaser pursuant to any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, license, lease or other agreement or instrument to which the Purchaser is a party or by which the Purchaser is bound, or to which any of the properties or assets of the Purchaser is subject, or (ii) result in any violation of the provisions of the Organizational Documents of the Company or the Purchaser, or any applicable Laws.

 

-4

 

 

4.3          Consents. No filing with, or consent, approval, authorization, order, registration, qualification or decree of, any court or Governmental Authority is necessary or required for the execution and delivery of this Agreement, the performance by the Purchaser of its obligations hereunder or the consummation of the transactions contemplated by this Agreement.

 

4.4          Purchaser’s Status. The Purchaser either (i) is an institutional “accredited investor” within the meaning of Rule 501(a) of Regulation D under the Securities Act, or (ii) is not a U.S. Person and is located outside of the United States, as such terms are defined in Rule 902 of Regulation S under the Securities Act.

 

4.5          Sophisticated Investor. The Purchaser has such knowledge and experience in financial and business matters to make an informed decision with respect to the Purchaser’s purchase of the Sale Shares. The Purchaser is a sophisticated investor and has independently evaluated the merits of its decision to purchase the Sale Shares pursuant to this Agreement. In connection with such purchase, the Purchaser is not relying on the Seller or its representatives in any respect in making its decision to make such purchase except for such representations and warranties of the Seller made under Article III.

 

4.6          Purchase for Investment. The Purchaser is acquiring the Sale Shares for investment for its own account and not with a view toward any resale or distribution of any part thereof except in compliance with the Securities Act. The Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to any Person with respect to the Sale Shares. The Purchaser hereby acknowledges that the Sale Shares have not been registered pursuant to the Securities Act and may not be transferred in the absence of such registration thereunder or an exemption therefrom, unless in a transaction not subject to the Securities Act.

 

Article V
COVENANTS AND AGREEMENTS

 

5.1          Further Cooperation. Subject to the terms and conditions provided herein, each of the Parties shall use commercially reasonable efforts to promptly take, or cause to be taken, all necessary actions proper under applicable Laws, to obtain consents or provide notices or effect registrations and filing or remove impediments necessary to consummate the transactions contemplated hereby as promptly as practicable following the date hereof, including, without limitation, to notify the Company upon the date hereof and request its cooperation in the consummation of the transactions contemplated hereby. Each Party shall execute and deliver at the Closing documents required to be executed and delivered by it as Closing conditions, shall take all steps necessary and proceed diligently and act in good faith to satisfy each condition in Article VI and shall not take or fail to take any action that could reasonably be expected to result in the non-fulfillment or delay of any such condition.

 

-5

 

 

5.2          Notification. Each Party will notify the other Parties as soon as reasonably practicable (but in any event prior to the Closing Date) in the event it comes to such Party’s attention that any of such Party’s representations or warranties set out in this Agreement has ceased to be true and accurate in any material respect or there has been any breach by such Party of any of its agreements contained in this Agreement or any failure by such Party to comply with any of its obligations contained herein.

 

5.3          Appointment of directors of the board of the Company. Each Party shall use its reasonable best efforts to procure that a Person nominated by the Purchaser and a Person nominated by the Seller be appointed or elected as members of the Board as soon as possible after the Closing.

 

5.4          Exclusive Dealing. During the period from the date of this Agreement through (i) the Closing Date or (ii) the termination of this Agreement, the Seller shall not take or permit any of its affiliates, representatives, consultants, financial advisors, attorneys, accountants or other agents to take, any action to solicit, encourage, initiate or engage in discussions or negotiations with, or provide any information to enter into any agreement with or cooperate in any other way with any Person (other than the Purchaser, its affiliates and their respective representatives) concerning any Acquisition Proposal. The Seller shall notify the Purchaser promptly (but in no event later than forty-eight (48) hours) after receipt by the Seller or its representatives of any Acquisition Proposal from any Person other than the Purchaser. The Seller shall keep the Purchaser informed, on a current basis, of any material changes in the status of any such Acquisition Proposal or request. The Seller shall, and shall cause its representatives to, immediately cease and cause to be terminated any existing discussions or negotiations with any Person (other than the Purchaser) conducted heretofore with respect to any Acquisition Proposals. To the extent it has not already done so, the Seller shall, or cause its representatives to, promptly request that all confidential information previously furnished to any Person be promptly returned or destroyed. The Seller agrees not to, without the prior written consent of the Purchaser, release any Person from, or waive any provisions of, any confidentiality agreement entered into in connection with any potential Acquisition Proposal to which the Seller is a party.

 

5.5          Confidentiality. Except as otherwise required by applicable Law or Order, or regulations of stock exchange, or otherwise permitted by this Agreement, each Party shall not disclose to any third party any content or information in connection with this Agreement and the transactions contemplated hereby, or non-public information relating to the other Party (“Confidential Information”) without the prior consent of the other Party and shall keep Confidential Information strictly confidential. Each Party may disclose Confidential Information to its and its affiliates’ directors, officers, managers, employees, investors and potential investors, professional advisers, accountants and lawyers on a need-to-know basis; provided, however, that the disclosing Party shall ensure that such persons are subject to the same confidentiality obligation as they were under this Agreement. Notwithstanding anything herein to the contrary: (i) the Parties may disclose Confidential Information to the Company’s directors and officers on a need-to-know basis for purposes of performing any agreement, covenant and obligation hereunder; and (ii) the Parties acknowledge that certain Parties may be required to file with the U.S. Securities and Exchange Commission (“SEC”) such schedules and forms as may be required under the Exchange Act, which may need to contain as an exhibit thereto a copy of this Agreement, and nothing contained in this Section 5.5 is intended to limit or restrict such ability to file such schedules and forms or any amendments thereto. To the extent practicable and permitted by applicable Law, prior to the Seller’s disclosure of Confidential Information to a Government Authority or stock exchange (including the Seller’s disclosure to the SEC), the Seller shall notify the Purchaser in advance of such disclosure and shall obtain the Purchaser’s consent with respect to the contents of such disclosure, which consent shall not be unreasonably withheld or delayed by the Purchaser.

 

5.6          No Claim by the Seller. Following the Closing, which shall have occurred in accordance with the terms and conditions of this Agreement, of the Seller hereby irrevocably waives its right to, and undertake that the Seller shall not, make any claim (whether directly or indirectly through third parties) or take any other action against the Purchaser, its and its affiliates’ directors, officers, employees, shareholders, owners, representatives, agents or advisors, for any reason or cause, other than with respect to any inaccuracy in or breach of any representation or warranty of the Purchaser under this Agreement, in connection with the Sale Shares, this Agreement or the transactions contemplated hereby.

 

-6

 

 

5.7          Stock-Splits, Reclassification or Reorganization. If, after the date hereof and prior to Closing, the number of Common Stock is increased or decreased as a result of a stock dividend, a subdivision or split-up of Common Shares, a consolidation, combination, reverse stock split, reorganization or reclassification of Common Shares, a merger with or into or consolidation with another corporation undertaken by the Company, or any other similar event, the number of Sale Shares to be sold by the Seller hereunder and the Purchase Price shall be appropriately and equitably adjusted to reflect the intent of the agreement set forth in Section  2.1.

 

Article VI
CONDITIONS TO CLOSING

 

6.1          Conditions to the Seller’s Obligations. The obligation of the Seller to proceed with the Closing is subject to the fulfillment, at or before the Closing, of each of the following conditions (all or any of which may be waived in whole or in part by the Seller in its sole discretion):

 

(a)           Representations and Warranties. Each of the representations and warranties made by the Purchaser in this Agreement shall be true and correct in all respects on and as of the Closing Date as though such representation or warranty was made on and as of the Closing Date.

 

(b)           Performance. The Purchaser shall have performed and complied with each agreement, covenant and obligation required by this Agreement to be so performed or complied with by it in all material respects.

 

(c)           Injunctions; Illegality. No provision of any applicable Law or Order shall restrain, enjoin or otherwise prohibit the consummation of the Closing.

 

6.2          Conditions to the Purchaser’s Obligations

 

. The obligation of the Purchaser to proceed with the Closing is subject to the fulfillment, at or before the Closing, of each of the following conditions (all or any of which may be waived in whole or in part by the Purchaser in its sole discretion):

 

(a)           Representations and Warranties. Each of the representations and warranties made by the Seller in this Agreement shall be true and correct in all respects on and as of the Closing Date as though such representation or warranty was made on and as of the Closing Date.

 

(b)           Performance. The Seller shall have performed and complied with each agreement, covenant and obligation required by this Agreement to be so performed or complied with by the Seller in all material respects.

 

(c)           Injunctions; Illegality. No provision of any applicable Law or Order shall restrain, enjoin or otherwise prohibit the consummation of the Closing.

 

-7

 

 

(d)          Acquisition of Sale Shares. The Seller has delivered to the Purchaser written evidences to the satisfactory of the Purchaser (including the register of members of the Company duly certified by the transfer agent or a director of the Company) certifying that the Seller has become the owner of the Sale Shares.

 

(e)           Company Cooperation. Upon notification by the Parties after the date hereof to the Company of the transactions contemplated hereby, the Company or its representative has not expressly or impliedly indicated, and no event, circumstance, or communication with the Company or its representative has occurred that, individually or in the aggregate, would indicate, that the Company may object, refuse or otherwise not cooperate with the Parties to give effect to the transactions contemplated hereby.

 

(f)            No Material Adverse Effect. Since the date of this Agreement, no event or circumstance has occurred that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect on the Company (the “Company Material Adverse Event”).

 

(g)           Closing Certificate. The Seller has delivered to the Purchaser a certificate, dated as of the Closing Date, signed by an authorized officer of the Seller, certifying that the conditions specified in Section 6.2(a) through Section 6.2(f) are satisfied.

 

Article VII
INDEMNIFICATION

 

7.1          Indemnification by the Seller

 

. The Seller shall indemnify the Purchaser and each of its and its affiliates’ directors, officers, employees, shareholders, owners, representatives, agents and advisors (collectively, the “Indemnified Parties”) and save and hold each of them harmless against any direct and indirect losses (the “Losses”) suffered, incurred or paid by the Indemnified Parties (including reasonable legal fees), arising from, as a result of or in connection with misrepresentation or breach of representation or warranty or breach of covenants or agreements by the Seller hereunder.

 

7.2          Exclusive Remedies

 

. Notwithstanding any other provisions contained herein, the remedies contained in this Article VII shall be the sole and exclusive monetary remedy of the Indemnified Parties for any claim arising out of or resulting from this Agreement, except that no limitation or exceptions with respect to the obligations or liabilities provided hereunder shall apply to a Loss incurred by any Indemnified Party arising due to the fraud or fraudulent misrepresentation of the Seller; provided, however, that the Parties shall be entitled to specific performance or other equitable remedies pursuant to Section 8.7.

 

Article VIII
GENERAL PROVISIONS

 

8.1          Termination.

 

(a)           This Agreement may be terminated (i) prior to the Closing by mutual written consent of the Parties, (ii) by either Party if the Closing shall not have occurred within three (3) months from the date hereof (or a later date mutually agreed by the Seller and the Purchaser) (the “Long Stop Date”), or (iii) by the Seller, if the Purchaser shall have failed to pay in full the Purchase Price by the Closing Date; provided that the Seller shall not have the right to terminate this Agreement pursuant to Section 8.1(a)(ii) if the Seller is then in material breach of this Agreement.

 

-8

 

 

(b)           In the event of termination of this Agreement as provided in Section 8.1(a), subject to Section 8.3, this Agreement shall forthwith become void, and there shall be no liability or obligation on the part of the Parties; provided that (i) each Party shall remain liable for any breaches of this Agreement or in any other instruments delivered pursuant to this Agreement prior to its termination; and (ii) the provisions of Section 5.5 and this Article VIII shall remain in full force and effect and survive any termination of this Agreement.

 

8.2          Amendment; Waivers. This Agreement may be amended, supplemented or changed, or any provisions hereof can be waived, only by written instrument making specific reference to this Agreement signed by the Party against whom enforcement of any such amendment, supplement, modification or waiver is sought. The waiver by any Party hereto of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. No failure on the part of any Party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by Law.

 

8.3          Expenses and Fees.

 

(a)           Subject to Section 8.3(b) and Section 8.3(c), all fees and expenses incurred in connection with the transactions contemplated by this Agreement, including all legal, accounting, financial advisory, consulting and all other fees and expenses of third parties incurred by a Party in connection with the negotiation and effectuation of the terms and conditions of this Agreement and the transactions contemplated hereby (the “Expenses”), shall be the obligation of the respective Party incurring such fees and expenses.

 

(b)           If the Closing shall not have occurred due to reasons attributable to the Seller by the Long Stop Date, the Seller agrees to reimburse, or cause its designee to reimburse the Purchaser, any Expenses incurred by or on behalf of the Purchaser up to an amount of US$150,000 immediately after the Long Stop Date.

 

(c)           If the Closing shall not have occurred due to reasons attributable to the Purchaser by the Long Stop Date, the Purchaser agrees to reimburse, or cause its designee to reimburse the Seller, any Expenses incurred by or on behalf of the Seller up to an amount of US$150,000 immediately after the Long Stop Date.

 

8.4          Notices. All notices and other communications hereunder by any Party to the others shall be in writing and shall be deemed given when delivered personally or by international courier, or sent by facsimile or electronic mail to the contact details set forth on the signature pages and shall be copied to the additional contact as set forth thereon as well (or at such other address for a Party as shall be specified by like notice); provided, however, that notices sent by mail will not be deemed given until received.

 

8.5          Counterparts; Facsimiles. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each Party and delivered to the other Parties, it being understood that all Parties need not sign the same counterpart for it to be effective among the Parties. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more Parties hereto and delivered by such Party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such Party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes.

 

-9

 

 

8.6          Severability. In the event that any provision of this Agreement or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the Parties. The Parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.

 

8.7          Specific Performance. The Parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to seek an injunction or injunctions without the need to post any bond or other financial assurances in order to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state, province or other locale, both U.S. and non-U.S., having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity.

 

8.8          Governing Law; Dispute Resolution. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the principle of conflict laws thereunder. All disputes between the Parties arising out of or relating to this Agreement shall be finally settled at the Hong Kong International Arbitration Centre (the “Centre”) in accordance with the Rules of Arbitration of the Center by three arbitrators appointed in accordance with said Arbitration Rules. The place of arbitration shall be in Hong Kong. The arbitration shall be conducted in English. The resolution of any dispute by arbitration pursuant to this Section 8.8 shall be non-appealable, final, binding and conclusive on the Parties to such dispute and may be enforced and entered as a judgment in any court of law with jurisdiction thereof. Notwithstanding the foregoing, any Party shall be free to seek interim or permanent equitable or injunctive relief, or both, from any court having jurisdiction to grant the same.

 

8.9          Survival. All of the representations, warranties, covenants and agreements of the Parties in this Agreement shall survive the Closing.

 

8.10        Section and Other Headings. The article, section, schedule and other headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

 

8.11        No Third-Party Beneficiaries; Assignment. This Agreement and the exhibits and schedules hereto: (a) are not intended to confer upon any other Person any rights or remedies hereunder; and (b) shall not be assigned by operation of law or otherwise.

 

8.12        No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the Parties to express their mutual intent, and no rules of strict construction will be applied against any Party.

 

[Signature Pages Follow]

 

-10

 

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.

 

  CDH Utopia Limited

 

  By: /s/ William Hsu
  Name: William Hsu
  Title: Director

 

  One Temasek Avenue,
  #18-02, Millenia Tower,
  Singapore 039192
  Telephone: +65 6572 8750
  Fax: +65 6238 0132
  E-mail: liquan@cdhfund.com
  Attention: Quan Li

 

[Signature Page to the Share Purchase Agreement]

 

 

 

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.

 

  1Globe Biomedical (Hong Kong) Company Limited
   
  By: /s/ Pengfei Li
  Name: Pengfei Li
  Title: Chairman Assistant

 

  8F, Block B, Techart Plaza,
  No.30 Xueyuan Road, Haidian District,
  Beijing, 100083, P.R. China
  Telephone: +86-10-61196291
  Fax: +86-10-61196391
  E-mail: Stella.wang@1globe-hk.com
  Attention: Stella Wang

 

[Signature Page to the Share Purchase Agreement]

 

 

 

EX-99.C 4 tm2038785d1_ex99-c.htm EXHIBIT C

 

Exhibit C

 

Strictly Confidential

 

 

November 24, 2020

 

1Globe Biomedical (Hong Kong) Company Limited

8F, Block B, Techart Plaza,

No.30 Xueyuan Road, Haidian District,

Beijing, 100083, P.R. China

Attention: Stella Wang

 

Subject: Letter Agreement Regarding the Proposed Investment by CDH

 

Dear Sir and/or Madam:

 

Reference is hereby made to the share purchase agreement, dated as of the date hereof (the “SPA”), entered into by and among CDH Utopia Limited (the “Purchaser”) and 1Globe Biomedical (Hong Kong) Company Limited (the “Seller”), pursuant to which the Purchaser shall purchase from the Seller in aggregate 6,000,000 Common Shares (the “Sale Shares”) of Sinovac Biotech Ltd. (the “Company”). Capitalized terms used herein without definition shall have the same meanings as in the SPA.

 

This Letter Agreement (this “Letter”) shall evidence the understanding and further agreement among the parties hereto as follows:

 

1.            Guarantee. For so long as the Purchaser holds any Sale Shares, CDH Investment Advisory Private Limited (the “CDH Guarantor”) undertakes to the Seller that it will procure that the Purchaser shall perform its obligations under Section 3 of this Letter. The CDH Guarantor hereby represents and warrants to the Seller as follows: (w) the CDH Guarantor is a limited liability company duly organized, validly existing and in good standing under the Law of Singapore; (x) the CDH Guarantor has full power and authority to enter into this Letter and to perform its obligations hereunder; (y) the execution and delivery by the CDH Guarantor of this Letter and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action on the part of the CDH Guarantor to the extent applicable; and (z) this Letter has been duly executed and delivered by the CDH Guarantor and, assuming due execution and delivery of this Letter by the Seller, constitutes a valid and binding obligations of the CDH Guarantor, enforceable against the CDH Guarantor in accordance with its terms.

 

2.            Compensation and Reimbursement. Upon occurrence of the Closing, the Purchaser agrees to make to the Seller or its designee a lump sum payment of US$135,600,000 (the “Compensation”), in immediately available funds by wire transfer into an account designated by the Seller, within three (3) Business Days after the transfer of the Sale Shares as contemplated by the SPA and the ownership of the Sale Shares by the Purchaser have been properly reflected in the Company’s or its transfer agent’s books and records, as compensation and reimbursement for the costs and expenses incurred by the Seller and its affiliates in connection with the legal proceedings among the Seller and its affiliates on the one hand and the Company on the other hand prior to the date hereof.

 

 

 

 

3.            Voting Arrangement. The Purchaser hereby undertakes that, upon the Closing, in the event it receives any document whereby a vote, resolution, consent or other approval (each a “Shareholder Vote”) of the Purchaser with respect to the Sale Shares then held by the Purchaser is sought (collectively, the “Voting Documents”), the Purchaser shall (a) cause a copy of such Voting Documents to be promptly provided to the Seller, and (b) cast such votes at any Shareholder Vote representing seventy percent (70%) of the Sale Shares then held by the Purchaser in accordance with the voting instructions given by the Seller, to the extent such voting instructions shall have been given to the Purchaser promptly and within the period prescribed in the relevant Voting Document. For the avoidance of doubt, nothing in this Letter shall limit the Purchaser’s right to cast such votes at any Shareholder Vote representing the remaining thirty percent (30%) of the Sale Shares then held by the Purchaser in its full discretion. In case of any dispute between the Purchaser and the Seller arising out of or in connection with any Shareholder Vote, the parties hereto shall use commercially reasonable efforts to ensure that the Purchaser and the Seller may each cast votes representing thirty percent (30%) and seventy percent (70%), respectively, of the Sale Shares then held by the Purchaser in such Shareholder Vote.

 

4.            Commitment.

 

a.            The Seller hereby undertakes to cooperate with the Company and the Purchaser to ensure that the transactions contemplated by the SPA are properly reflected in the Company’s or its transfer agent’s books and records in a timely manner.

 

b.            Each of parties hereto hereby undertakes that it shall use commercially reasonable efforts to ensure that the Sale Shares shall not be unreasonably diluted upon the Closing.

 

5.            Confidentiality. Except as otherwise required by applicable Law or Order, or regulations of stock exchange, or otherwise permitted by this Letter, each party hereto shall not disclose to any third party any content or information in connection with this Letter and the transactions contemplated hereby, or non-public information relating to the other party (“Confidential Information”) without the prior consent of the other party and shall keep Confidential Information strictly confidential. Each party may disclose Confidential Information to its and its affiliates’ directors, officers, managers, employees, investors and potential investors, professional advisers, accountants or lawyers on a need-to-know basis; provided, however, that the disclosing party shall ensure that such persons are subject to the same confidentiality obligation as they were under this Letter. To the extent practicable and permitted by applicable Law, prior to the disclosure of Confidential Information by any party hereto to a Government Authority or stock exchange, such disclosing party shall notify the other parties in advance of such disclosure and shall obtain such other parties’ consent with respect to the contents of such disclosure, which consent shall not be unreasonably withheld or delayed by such other parties.

 

6.            Termination. This Letter may be terminated (i) by mutual written consent of the parties hereto or (ii) automatically upon the termination of the SPA. In the event of termination of this Letter, this Letter shall forthwith become void, and there shall be no liability or obligation on the part of the parties hereto; provided that (x) each party hereto shall remain liable for any breaches of this Letter prior to its termination; and (y) the provisions of Sections 6 (Confidentiality), 7 (Termination), 8 (Amendment; Waivers), 9 (Governing Law; Dispute Resolution) and 10 (Miscellaneous) shall remain in full force and effect and survive any termination of this Letter.

 

-2-

 

 

7.            Amendment; Waivers. This Letter may be amended, supplemented or changed, or any provisions hereof can be waived, only by written instrument making specific reference to this Letter signed by the party hereto against whom enforcement of any such amendment, supplement, modification or waiver is sought. The waiver by any party hereto of a breach of any provision of this Letter shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. No failure on the part of any party hereto to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by Law.

 

 

8.            Governing Law; Dispute Resolution. This Letter shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the principle of conflict laws thereunder. All disputes between the Parties arising out of or relating to this Letter shall be finally settled at the Hong Kong International Arbitration Centre (the “Centre”) in accordance with the Rules of Arbitration of the Center by three arbitrators appointed in accordance with said Arbitration Rules. The place of arbitration shall be in Hong Kong. The arbitration shall be conducted in English. The resolution of any dispute by arbitration pursuant to this Section 9 shall be non-appealable, final, binding and conclusive on the parties to such dispute and may be enforced and entered as a judgment in any court of law with jurisdiction thereof. Notwithstanding the foregoing, any party hereto shall be free to seek interim or permanent equitable or injunctive relief, or both, from any court having jurisdiction to grant the same.

 

9.            Miscellaneous.

 

a.            Notices. All notices and other communications hereunder by any party hereto to the others shall be in writing and shall be deemed given when delivered personally or by international courier, or sent by facsimile or electronic mail to the contact details set forth on the signature pages and shall be copied to the additional contact as set forth thereon as well (or at such other address for a party as shall be specified by like notice); provided, however, that notices sent by mail will not be deemed given until received.

 

b.            Counterparts; Facsimiles. This Letter may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties, it being understood that all parties hereto need not sign the same counterpart for it to be effective among the parties. A facsimile, telecopy or other reproduction of this Letter may be executed by one or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes.

 

c.            Severability. In the event that any provision of this Letter or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Letter will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the parties hereto. The parties hereto further agree to replace such void or unenforceable provision of this Letter with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.

 

-3-

 

 

d.            Specific Performance. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Letter were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties hereto shall be entitled to seek an injunction or injunctions without the need to post any bond or other financial assurances in order to prevent breaches of this Letter and to enforce specifically the terms and provisions hereof in any court of the United States or any state, province or other locale, both U.S. and non-U.S., having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity.

 

e.            Entire Agreement. This Letter and the SPA constitute the entire agreement among the parties hereto with respect to the subject matter hereof and supersede all prior agreements and understandings both written and oral, between the parties hereto with respect to the subject matter of this Letter and the SPA.

 

[Signature Pages Follow]

 

-4-

 

 

If the foregoing meets with your approval, kindly countersign this letter agreement below to indicate your acceptance and agreement to its terms.

 

  Very truly yours,
   
  CDH Utopia Limited
   
  By: /s/ William Hsu
  Name: William Hsu
  Title: Director
   
  CDH Investment Advisory Private Limited
   
  By: /s/ Shangzhi Wu
  Name: Shangzhi Wu
  Title: Director
   
  One Temasek Avenue,
  #18-02, Millenia Tower,
  Singapore 039192
  Telephone: +65 6572 8750
  Fax: +65 6238 0132
  E-mail: liquan@cdhfund.com
Attention: Quan Li

 

[Signature Page]

 

 

 

Agreed and accepted as of

the date first above written:

 

1Globe Biomedical (Hong Kong) Company Limited

 

By: /s/ Pengfei Li                                             
Name: Pengfei Li  
Title: Chairman Assistant  
   
Address: 8F, Block B, Techart Plaza,  
No.30 Xueyuan Road, Haidian District,  
Beijing, 100083, P.R. China  
Telephone: +86-10-61196291  
Fax: +86-10-61196391  
E-mail: Stella.wang@1globe-hk.com  
Attention: Stella Wang  

 

[Signature Page]

 

 

EX-99.D 5 tm2038785d1_ex99-d.htm EXHIBIT D

 

Exhibit D

 

 

 

December 18, 2020

 

1Globe Biomedical (Hong Kong) Company Limited

8F, Block B, Techart Plaza,

No.30 Xueyuan Road, Haidian District,

Beijing, 100083, P.R. China

Attention: Stella Wang

 

Subject: Amendment to the Letter Agreement Regarding the Proposed Investment by CDH

 

Dear Sir and/or Madam:

 

Reference is made to (i) the share purchase agreement, dated as of November 24, 2020 (the “SPA”), entered into by and among CDH Utopia Limited (the “Purchaser”) and 1Globe Biomedical (Hong Kong) Company Limited (the “Seller”), pursuant to which the Purchaser shall purchase from the Seller in aggregate 6,000,000 Common Shares (the “Sale Shares”) of Sinovac Biotech Ltd. (the “Company”) and (ii) the letter agreement, dated as of November 24, 2020 (the “Side Letter”) issued by the Purchaser and CDH Investment Advisory Private Limited (the “CDH Guarantor”) to the Seller. Capitalized terms used herein without definition shall have the same meanings as in the SPA and the Side Letter.

 

The parties hereto desire to amend the Side Letter pursuant to the terms contained in this Amendment to the Letter Agreement (this “Amendment”) as follows:

 

1.                   Amendment.

 

a.Section 2 of the Side Letter shall be deleted and replaced in its entirety with the following:

 

Compensation and Reimbursement. Upon occurrence of the Closing, the Purchaser agrees to make to the Seller or its designee a lump sum payment of US$135,600,000 (the “Compensation”), in immediately available funds by wire transfer into an account designated by the Seller, within three (3) Business Days after the transfer of the Sale Shares as contemplated by the SPA and the ownership of the Sale Shares by the Purchaser have been properly reflected in the Company’s or its transfer agent’s books and records, as compensation and reimbursement for, among other terms and conditions, the total costs and expenses that have been incurred and are estimated to be incurred by the Seller and its affiliates in connection with the legal proceedings among the Seller and its affiliates on the one hand and the Company on the other hand until the final resolution of such proceedings.”

 

b.The following shall be added as a new Section 4A after Section 4 of the Side Letter and before Section 5 of the Side Letter:

 

 

 

 

Exhibit D

 

Future Proceeds. The parties hereto agree that, subject to detailed arrangement to be further discussed among the parties, (a) the Purchaser shall be entitled to the greater of (i) thirty percent (30%) of all cash consideration received by the Purchaser in respect of the disposal or divestment of (x) the Sale Shares or (y) any securities, properties or assets received by the Purchaser in exchange for any Sale Shares (such total cash consideration, the “Proceeds”) or (ii) such portion of the Proceeds that would allow the Purchaser to generate a Net Return which yields two (2) times the Investment Cost, or the entire Proceeds if the Proceeds are insufficient to generate such Net Return; and (b) the remainder of the Proceeds upon deduction of the distribution to the Purchaser pursuant to item (a) above shall be distributed to the Seller within a period to be agreed by the parties hereto. For the purpose of this Section 4A, (A) the “Investment Cost” shall include the Purchase Price and the Compensation; and (B) “Net Return” shall mean the gross proceeds generated by the disposals or divestments net of (m) the Investment Cost and (n) any transaction costs and expenses reasonably incurred by the Purchaser or its affiliates in connection with the transactions contemplated hereby and by the SPA (including any advisor’s fees and expenses).”

 

2.                   No further Amendment. The Parties agree that all other provisions of the Side Letter shall, subject to Section 1 of this Amendment, continue unmodified, in full force and effect and constitute legal and binding obligations of the parties to the Side Letter in accordance with their terms. This Amendment forms an integral and inseparable part of the Side Letter.

 

3.                   References. All references to the Side Letter (including “hereof,” “herein,” “hereunder,” “hereby” and “this Letter”) in the Side Letter shall refer to the Side Letter as amended by this Amendment.

 

[Signature Pages Follow]

 

 

 

 

Exhibit D

 

If the foregoing meets with your approval, kindly countersign this amendment below to indicate your acceptance and agreement to its terms.

 

  Very truly yours,
   
  CDH Utopia Limited
   
  By: /s/ William Hsu
  Name: William Hsu
  Title: Director
   
  CDH Investment Advisory Private Limited
   
  By: /s/ Shangzhi Wu
  Name: Shangzhi Wu
  Title: Director
   
  One Temasek Avenue,
  #18-02, Millenia Tower,
  Singapore 039192
  Telephone: +65 6572 8750
  Fax: +65 6238 0132
  E-mail: liquan@cdhfund.com
Attention: Quan Li

 

[Signature Page]

 

 

 

 

Exhibit D

 

Agreed and accepted as of  
the date first above written:  
   
   
1Globe Biomedical (Hong Kong) Company Limited  
   
   
   
By: /s/ Pengfei Li  
Name: Pengfei Li  
Title: Chairman Assistant  
   
Address: 8F, Block B, Techart Plaza,  
No.30 Xueyuan Road, Haidian District,  
Beijing, 100083, P.R. China  
Telephone: +86-10-61196291  
Fax: +86-10-61196391  
E-mail: Stella.wang@1globe-hk.com  
Attention: Stella Wang  

 

[Signature Page]

 

 

GRAPHIC 6 tm2038785d1_ex99-cimg01.jpg GRAPHIC begin 644 tm2038785d1_ex99-cimg01.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" ] %T# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BOY_/\ M@J-_P<:?L(_\$PO%6L_!GQ"_B[X_?M+Z/IEM>ZA\%_A+_9/V?PA=:G:07^BV M7Q3\?ZSF6?B_P 7V=C<:;J%YX573]6L+N[^N?\ @M!^ MV%XC_80_X)D?M8_M+>")7M_'WA+P+I?A7X?W44A6YTOQO\5O&/AWX5^&_$=F M<;1<>%=0\8CQ5:^?NMMVAC=:WB_Z)+_F ?\ !"C]FM?V]_\ @K?^SAX3^+>H M-X]T2T\;7OQR^*X\^++WX@:1\-$'BN_T76YM1FN;O6#XGU*WL++6[G4[E M_P#B53ZE>W;.+8%@#^][]FW_ (*?_P#!G_#[2?&P@UN"]&O-4^'> MC:)>Z1-;7^GZW?Z?JMA?G]#OV./'?PS_:6\>>/_ !I9>3IMQ_PCMIX:\*W_ ,-]'MKJ_NM7B@-^=4N[2R_L M>]W"]L[^S^QWOZ0?$7QKHWPK^&_CGXBZS;SMH'PW\$^*/&NJ6NGPK]H;1_!^ MA7VNW\-C#N6'SS8Z?(MHAP"=J@8!Q^9O[-7_ 5<\'_M$_'+P5\ 4^$>O^"_ M&'C67Q/-!>7_ (PTO4M)M-'\*>"M:\1ZI>6Y_LO2=1UB^_MC2!H5I9Z99-9& MRGN=;OM9L[RS&BW@!^7O_!=S_@X8^+W_ 2&_:?^%/P&\"?LV_#OXQ:)\1/@ M+8?%VY\3>+O'>N>'M2L]7OOB%X_\'#0H-,TC3KLBPL[3P=;ZE]LN2OVVZU=K M.Q*C2+H77L?[)'_!0C_@M?\ MP?LJ?"G]KKX$?L<_P#!/4?#SXL:?KVN>&M$ M\9_M._&W2O&]WI_AOQ7XB\-WME/I=O\ !L^'-'U&[N?#MYIEE<77BZ\M/MBK MJ%Z+.QNC9VGS]_P7H_X-YOCS_P %_A+\*/#G@/]G[PY\'M M4T?Q]IOC'5-9N]5TKXF_$;QE=:S86_A_2[K3A9'2?',%N/M.IB[O;[2_L;1V M=F1>U^XW_!++]CSQA^P#^P-^SM^R#X]\?:1\3?%?P6\/>+-'U7QKX,O&EC!I5CJ9;4!;Z'IOB6R\/[[H(][_ &4+[[+:?:A:* ?SJ_%_ M_@Z'_:A_8!_:'L?@+_P5(_X)9Z_\%;?5Y;W6+'QU\'OC;8^-(K_P0(KV"PU_ MP#I>M^$K3P5\6H/[9AL-,UNZTOXL^#SHJRZB]]HHUNSMO#=Y_47^R#^V5^SI M^W=\$_#'[0?[,/Q&TWXC?#CQ)"4-U;+/I^N>&]9BV_;_ IXQ\.Z@MMJGAWQ M1I4Y:VO=+U*U3[HO;"[O-/NK.^NOR_\ ^#DC]ECX?_M,_P#!(_\ :EU3Q7HN MES^+_P!GCP7>?M!_##Q/BZK<2?"[]K;1_%WPS^( M_AA[R*+2Y]4\-^"/%'Q \ >*88+A6M_[?T#Q!X>.DV;VYM;MM(\4Z[8J[&Y% MHP!_7_\ \%Y_^"_?Q5_X) ?&GX(?"CP#^SWX#^+UE\6_A3K?Q"N?$/C3Q5KN MCOI>J:7XKO\ P]!H]G8Z(N;BW;['!<7MU=FV-JMZK69O&M7LQ^N7_!*#]MW6 M_P#@HU^P+\"/VR/$/@?2/AQK7Q?'Q+>_\$:#JFI:[H^@GP+\8/'WPXMH;'6] M0MK*ZU8W5CX/M[N^NOLJ*FK7&HV053:M;+^2_P#P77_X-_/B-_P6%^.'P:^* M_A3]I?P;\$-+^$GPJNOAZ-!\2?#G5_&MYK5]JGC#7/$E]JPO].\2:!]@MQ;W M.E6EK:-]L+,EVP%D!_I?J4/C2U_X-GO^"*/PLTKXEV5U^UPKXGNO%PTJVT(>*A:W8ME8ZM>6QOA9V;7MW=@ Z; M_@O9_P %F/B%_P $=O!G[-GC/P-\$_!OQLC^-OBSXB>&M:TGQ;XHUSPDVD1^ M#M'\*:K8WNE7VCZ=JH=KG^V[RVO+>[LR%Q;.K##"XL_\$%?^"QWQ'_X+ _#G M]HKXB>/O@SX*^#,7P=\=^"_!NAZ)X.UWQ#XIEU.+Q#X?U77+Z_U;4M5MK4Y1 MK>U@L8;?2K*-5%T6ENBP6V_AB_X+P?\ !>/P'_P6+\ ?L^>$O"G[//B[X(S_ M 0\:>._$SW'B#QMHWC"#7K+QGH7AO2S: :;HFCM:W.F7'A[[07972\MKX+M MM#:%KS^BS_@R1LR/V1_VT[YHTCCG_:,\&6B7!CNW,SV7PRL97A+RW#Z:?LZW MT;XL[*VO0;DG4;J\@;3([, _I<_X*Q_L>:S^WO\ \$Z?VL/V3O#,MI'XR^*G MPU\SX?#4;^+3-,N/B7X \1Z'\3?AG9:OJD]O=KIND:EXZ\&>&[36+T6S&SL) MKJZ&"NZO\L#_ ())?'37O^"87_!77X&Z[^TAX?UCX0:5\/\ XH#X-_M*^%/& MA/@_4_!?ASQ++#X6U;5O%,6LZ9JNJ6T'@'Q3-X=^)^L6>FVMH^L6/A2>P2_T MG0M4NKZU_P!CG7->T/PQIMQK?B/6-,T#1K0PB]UC6]1M-+TNS%Q/%9P&YOK^ MXM;:V$]S-!:IN8!KNXA098C/XD?\%%_^"5W_ 2&_P""GVI_\)M^T9?^ -(^ M--KH$/A?2OCQ\*_C1H'@?XDVFBV,YFM+/4P-4U7P3XW735_T73V\>^#/$U[H MUD9[#1+O2+2Z8, ?LYJMCX?^)W@'4M/LM>>[\*_$'P?>V=GXF\(:Q 3=:#XJ MT::"#7O"^NV#7=L6N--U :CHFK6C7=KS:7UIO&TM\.? [_@F5^SW^S_\6?#G MQ>\!ZW\4'UWPE>^(+[1]#UG7_#5UX8CO?$7A75?!M]/-9:?X+TK4B;?0-;N; M6QMAJZV:^3;7;6ERZ$G\5OV>O^"3OQ]_8KT2T\ ?L8_\'%'B3X5_""T']GVW MPL^)_P &?VTW089IKBQT[PM#XQ^(^DZ9X)U#S9[DZUKW@W2-'U76+8 MVZ;K(V=FR?H5^R]\./VR/A/\;="\ M_8Q9?T;_ /!(;]J'XJ_MI?\ !-_]E7]J#XVV^FVWQ3^+W@C7M>\8)I&EV>CZ M1->V'CSQ7X*?C'JWB07(-]??8M4U35M7O+,'3OL!M1I-F% /HC_@Y_\ VW_AY^RQ_P $ MO/C/\(+OQ+X6/QJ_:YT>/X(_#'P%JMY#)J^J>'?$>IV$/Q3\8_V6.;71_"O@ M<:NJ>)M2:ST>Q\7:MX;LGOOM]Y96=U_([_P:1_\ !//XO_'+]OCPY^W$=)FT M'X"_LC#Q.;GQ7J<)CM_&OQ/\?^ O%7@?2?!/A:*YTV[M]?N-!T?Q'J?B;Q1= MVES9GP@1X::]O1>:QI-G>_T-Z+_P;UT/PCX)\'^ M+O!>E:'HVE6<0PL,%OJF;FZNL?:K_4[LW>K:M>S76HZE>7=]=7-VP!_*+_P< MN?\ !;#]OS_@F3^V!\#/A+^RC\0?AUX=\ ^.OV<-.^(_B'1/%'PTT#QIK,WB MV?XF_$OPM<7\U_KEINMM'N=(T+0H+&TL[D,M[I6I/> )<@7?Z=_L6>!/#_\ MP7R_X(C_ +/5]_P46_M/Q]>_&37?&?CGQ=?> _/^$,\'B3X9_'+XF>%O"LVB M#PNMKIPL=*T72(-, %I=V5]:'.I"[UVVNKZO!?\ @M!_P19_9S_X+"?'CX6_ M'#5/^"A?P]^ -S\,OA"?A1'H&G^&_!/Q*&MQ)XL\5>*K?6+G5;GXU^"5L5M[ MGQ2;8:5!I#$K!.S:ONO+46/ZR?\ !.'X0_ '_@GE^Q=\#_V/-*_:E^'?Q6M_ M@UI/B/3'^(NK:_X$\*7_ (IN/$7C;Q'XSN+N;P[8>*]9@TJWTW_A(QH&D6IU M?5[JTT;2M,6]O[R168@'\)G_ OV$O^"77PS_94\1_LF^'?&WA/Q+\ M9/%_Q*\.^)]-\7?$+5/'D>K:-X.T;P/J$-]86_B&VNKG2+BSO]6(O=3TW5;/ M)U:'3S87EE=YTC];?^#(MPW[+7[;\2"5-\.[A8?LV.EUN MAF^VYZQ?8?3 _5'_ (+;?\$P_@%_P62\.?LZ^';K]NWX:_LZQ_ GQ7X]\1WU MU8:=X6^)[>-;7Q]IG@[2I[/["?C)\/-.T?4=-M_!\"V&N7EIXFN@L[6=I:V5 MFUVMY[9_P1$_X)=_"3_@EA\(?C7\)OA1^U1:_M/VOQ'^)&B_$36M672O#&CI MX1NHO"=GX6@TT:5X<\7^*XU;4GT2\N_M]W>6DES%!#8)9?\ $IDN[L ^C_\ M@L5\5O'7P*_X)H?M>_&[X97'AJS^(?PG^%-]X[\'W7C#PAX:\=^'K;6-$U+3 M-LU[X6\8Z+K^@ZD5MY[G[&MYI;!;W[,^Y1DG\_?VUIOCW\"-,_8S^.7[,_PQ M^!WQJ^&G@_\ 9_\ &WQF_;4^!>I_ WX(0GXM?##PUI_P8L-=^)'P>\?:1X T MBZ\,?'>UM_B-XHU[P5X%LR/ ?Q+2QNK&R\,6J^'[O2/$O[V?%;P&?B;X!\0^ M!'N-"MH/$=JME=2>)_!>A_$#0FA6X@F\N_\ "'B;=H6L0,8E'V75;:YM<994 M%XMM)M-T_QM_P46_9D^'OQ(A\-ZCHF@W_C#PE^SWX:^(EM MX2O-4-[JFFZ3_P )!XUL]3_X1^[UCPI-=ZS:_9+NRO=7\.W%_?%K[2._A_P",AX,^%_@;PUK/B71I[G0S_P ( M[8+>7=CU?[?%7A/2WT'XY>-?VM/V>/!.JZ-X9^ O[$_M#?M*:#H8^!RZ7XY^&WC?X$Z1X_\&^!O&/AWX7V?C322?#7_"8Z';>* M]0UO6+.[-Y=_I)I_PE^)GC'P7IWAVP_:;^'GC+P/=:+X"WO[6X M/VE;H'[27A6,$6/VRSNP#\P/VOM \<^!OV5_@//^SAX/^''[2'Q)M_VA_$6F M?M!7'A+X;?L>:%^U1XA^%_@CP[\5/'WQ-\.?"3PUXI^$UU\"-0_:/^&)\*># M= \?^#;3X=V>L:S_ ,(IXN\+:!:^!?B)?Z1XB\->$?MLZQXE@_X)]?L._MJ? MLU_&[P7X$;XFS?L2^ _&_CSPM^Q?^S%IFE_&C3OVI_B;\%_#OBKXRZUX<^./ MP;^*_B/X,[F[UZ^\7V.EZ*M?J9J_PU^'GA M_1=3^$NO?M._LEZ+X6\+^(;_ $K5/A?K/P-^ .G^'O#'BWQ]X;\2W^N6E_X- MN/$MK;:-XG\>^#_&7B.YUBUNK.TO?$GAOQ'K=ZR75AK^K&][>X_9Z\0?&GX9 M:9X5/[1'PA^*'PKT\1:=H>DC]FOX*>// EA?^#KS[#I@TG29[K5_"%MJ'@RY ML9M)LK6UTH#1C!=61LUO;56M@#\U/^"A-OXP_84^$O[*?COPM:^$/B_X:_9_ MAUWXN_MLVNK?LM_LW:8OQT_9-\'?$/X!^ /C%XOU3PMX7^#PU/P/\4?A?X>^ M)>A?%+1E^#=IX!\'WFB^ ?'I\0:'=M;>!O#5GP7P.\Q^UVB_L]XO^$7Q?MM*\1>)_&?[4W@[ M3M&T[PQXB@\1^)/$_P _AE%IFD>!)4BU3Q39:WJNOZV;:V\(FQTK[3K:ZG= M?V2UE#/>:B#]DL[JR^6+Z7X'VWA&W^(NO_MZ_L?V'@?]I7PU:?$!_%?BOX8_ MLU:9H'Q]\):[#X6TBW\57FH:_P")+2U\ _AOTO[$FG_$G]H67]J+]F_P#:!^'GAO\ 9]_;5_9H^#OP MK^&GQ!\5:5^S)\ M<^!?B3XC?$#_ (7A8^#_ -MC]G2X\0?#?2]<^(^C?$;2 M/"MEKW_"+>,;FS\!^#O&'AS6O U]X)_T3Q)9WGZ%^'?V0/&GA?1_%&C^&?B[ M\,]'T7QKH.E^'M?T_2/V4O@_8V&JZ%H=IJEAH.FWMO9;;36=&T*PU6XM-$T/ M7K;5]'TFUQ8Z?96EA=WMI=]//\*/C5X;UB'6)_VLO"NAZSJVEZ-X8\Z^^!/P MYL)-;TSPYJ]]?:5IRG_A([.ZN!I;>(];M;&UM;I;.S_X2*Z=;+[;=!B ?D%^ MP[I_Q'?PG_P4Z^)OQE^+'P@^)G@W]DSX_P#[=?P$^&7@OXT?L]?LN>%O .CZ M#\"M-^'7C+X=?$[Q]XJ_9X^ /PR\67-OI6G:KXJTOXMVEII5Y:7=CJMN=-T6 MSUW1UN]9^K?^".'QA\?^/_!?QJ^'7Q6\)>*OAY\5?@]JGPNL/B!X0\6>$_V9 M?(OM=\8^"I_$'_"R/!'Q9_9.T_PA\*_B]\./'MM'"O@K5S\/_#/B72-)\/*N MN7OB.75HK^+UO1_"N@>#/&?C;]FC3OVSO@'X<^(GC7P_??&OQ[\(_P#A2GP MTKQ;XX\&>,)X/!NK_$[Q7X.MM:MKKQ3H_B:X@LO!NL^,/$^D7MWK+:7:V&H7 MUVIM7NOK;]FWX.6OP<\'ZAINB:W\/]:\/^(]1MO$FAR?#+X1^ OA)X<33KW2 M[/RK@:?X":+1O$-QJ)!O4UX?-)92VEF@D2U-Y=@';?&[XI2?!7X5^+_B=#\- MOBK\8;KPC96=Q;?#'X(>%X?&?Q3\9WE]J=CI-GH_@_P[?ZSX>TR[OVN+Z&ZO M+G5O$&C:-H^D07^M:YK.GZ/97EZG^:?\1[C6(_CM^T<4_9[UKP[X3\*^%_\ M@J'H&@>+=4\=Z-I5Y-XC^%7Q?^(W[;][\&9_#GP^\;6>AZ?\0?!NC_M0?#_X M=?$*[T'Q7XQ/AS69SHFA$GP_XQ\-U_IK_$+X?^$/BKX)\3_#KX@:);^(_!?C M+2+K0/$FAW$MW:)J&F7ZJD\27VFW-GJ>GW*$K/:ZCIEY9ZC8WL-M?6%U:W5O M'*/A^+_@DW_P3EM_AYX'^%5O^R3\++?X?_#/PS\8_"/@WPY;6VM6\6FZ+^T' MIWAO0_C9]LOH=834]?UGXF:/X.\/:7XL\3^(KS5?$^IV%@+:36!'=7WVH _' M3_@WVO\ QIX)_:)_:]_9V^,7P;U_X#?%KX1_L7?\$G_A]<>!/%5OITWBC5O# MOP/^!/Q&^$P\=Z[JOA][K0X)_&%Q96'B>TT"VO+N\\.#7;G0M0O;O6]+UE;3 MT#_@YWN/$6D_LJ?LS^(-"C\>74&G?M->);/Q-9^%IOB3:^'O[#U3]DS]II-, MU+Q1??"?PUXC\:"_T+Q_;>![SP79VMM9V6K>)/L]E?W^D!AXE\._OSX9^ 'P M:\)?&CXE_M#>&_A]H6D?&OXQ>'O!GA/XE_$:V2Z.O^+?#GPT34K;P3I5^TUS M+:0V^B1:Q>+&+&UM3> V_P#:!NS96)M?:* /\IO]JW3_ (7?!W4OV9?BS\/( M?B/\4+73O%/[,GB7]KQ?BC\!?&NH>+;O]M'Q5\#?AIX ^(WPUTKXT>./V*/$ M.AC6/AUH'_"<>*;[P9K_ ,3?B0?$GQ4\8:7KM]\%_$>N?#Z]_P"$E_N#_P"" M$?Q+_8ZOO@K\:O@E^R==?%Y=2^'OQ8U/XD?'3PQ\2/A;X]\":5\-/BI\:#<7 MM_\ #CP[JWB?]GK]G#0]0GTJV\*0:_>:#H/PR\--H]EXITR_O='7^UU-?KU\ M;?@!\'/VB/#&E>$/C9X!T7XA^&?#WCGP+\3=)T?6OMD=M;>-OAAXCM?&'@;6 MRUA=6^/OV"OBIX:\/:[K*ZYX8LIOB M5KWA7P_^V(O[&AU7X?:'H'BC1=:SHFB:*?$VE7BQK=_P 'WQ=T3X:_"#_@F]^S7XQUSXB?LX_M(Z;\??V$ M)?V^/+S_2A_:;_8?_9$_;,@\'6_ M[5/[.WPJ^.X\!:E=7?@J;XA^%K+6[SPXU]=Z=>:K9V%_($U!=%UZ[\/Z'/XE M\/-='0?$K:-I US3;]=-M!%J:;^QI^Q[HWBN^\>Z1^RA^S7I?CC4O"$7PYU/ MQGIOP,^&%EXLU+X?0Z';^'[?P)?^)(/"R:Q=^#8/#T-OH2>&)[R31?[)MX=. M%DMB@MJ /&_^" O!7AK M2[;Q)/?7OA3PM>_#+P1XE\57/@6XTK2+2?2SIGB^\3Q,U[I6I+J-G:7MG=6= MG^37_!Q3^Q5\;/CO\(Y?VG+?XW:#=? 3]D#X?'XG1?LAK^RO\#?BA\0/BM\9 M+'Q!JU@-3\#_ !V^*_@KXGZG\/KGQ3X>\1:%X9/A>V^&7CSPW?7OA?3FOO"V ML7^K6MWHG[;?LM?L1?LD_L4:/XST#]E'X ?#?X$:7\1/$%OXK\:P^ =#33Y_ M$FL#[7#IQU._N9+S49]-T%+R^7PYH'VL>'?#:ZCJ:^'](TL:E?\ VCJ/V@_V M6/@=^U-H>F>&?CQX0O?'/A[16OY;?0H_&GC_ ,)Z/>KJ@L3?6NO:9X*\5>'; M+Q187!TJS1M.\3PZQIXMA<6HM?+O;[[2 ?YR?Q-_9H^'?[0_Q]\0? B/Q=^R M3HW[4/Q$_P""BG[-W['7@_Q5X/UO3?%FEW'P6@^'&E^/O'UYJWP(U#PGX)MO MCOH_PO\ &-]I/@/X@^,O%.K>#KVS\8>%M#^'/PT\+_#?0M*LO FD?Z#W[ ?P M]_:Q^$W[-_A/X=?MCZY^SMK7Q.\%KI_A/PZO[+/A/Q-X1^%&C_#/PKX7\-^& M_"&DV6D>)[+3KJ/5E.E:GJ>H+I>D:)X?Q'_P $\?V$ M_&/PD\$? CQ'^R%^SOJ/P<^'=U?7OPY^'@^%'@^R\/?#S4-6O9]$=2U+5IY]2O]2\.MI=_>ZA*U]'O!'A3PSX+\):5: MZ!X5\(>'M%\+^&-"TY3#8:)X=\/Z;;:3HFD64>YBEIINFVEM:6R%B5BB49H "_]D! end GRAPHIC 7 tm2038785d1_ex99-d002.jpg GRAPHIC begin 644 tm2038785d1_ex99-d002.jpg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end